Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.090
-0.230 (-17.42%)
At close: Nov 20, 2026, 4:00 PM EST
1.050
-0.040 (-3.67%)
After-hours: Nov 20, 2026, 7:59 PM EST
Marker Therapeutics Employees
Marker Therapeutics had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Marker Therapeutics the 41,792nd largest employer in the world and 6,448th in the United States.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$462,746
Profits / Employee
-$1,710,638
Market Cap
18.17M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | -59 | -88.06% |
| Dec 31, 2022 | 67 | 11 | 19.64% |
| Dec 31, 2021 | 56 | 12 | 27.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Evaxion | 46 |
| Aardvark Therapeutics | 28 |
| LeonaBio | 19 |
| Atossa Therapeutics | 16 |
| Lipocine | 14 |
| TransCode Therapeutics | 12 |
| Cocrystal Pharma | 10 |
MRKR News
- 2 days ago - Marker Therapeutics awarded $16.2M CPRIT Product Development Research grant - TheFly
- 2 days ago - Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study - GlobeNewsWire
- 5 days ago - Marker Therapeutics Quarterly report: Q3 2026 - Filings
- 4 weeks ago - Marker Therapeutics awarded $2.6M FDA Orphan Products development grant - TheFly
- 4 weeks ago - Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer - GlobeNewsWire
- 2 months ago - Marker Therapeutics highlights expanded manufacturing support of CDMO partner - TheFly
- 2 months ago - Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies - GlobeNewsWire
- 3 months ago - Marker Therapeutics Quarterly report: Q2 2026 - Filings